30 subjects aged 12 to 45 years of age diagnosed with Tourette Syndrome with a YGTSS score > 20 during 30 days of baseline observation to be randomized to~continued present stable treatment (10 subjects) or~continued present stable treatment plus 10 mg of Sepranolone injected s.c. twice weekly for 12 weeks (20 patients) followed by one month of observation~Primary objective: to investigate the efficacy of Sepranolone to reduce tic severity in patients with Tourette Syndrome after 12 weeks of treatment with Sepranolone Change from baseline YGTSS total score at week 4, 8 and 12~Secondary objectives:~to investigate the efficacy of Sepranolone to reduce tic related impairment in patients with Tourette Syndrome after 12 weeks of treatment with Sepranolone Change from baseline YGTSS impairment score at week 4, 8 and 12~to investigate the efficacy of Sepranolone to reduce the urge to tic in patients with Tourette Syndrome at week 12 of treatment with Sepranolone Change from baseline PUTS score at weeks 4, 8 and 12~To evaluate the effect of Sepranolone on activities of daily living in patient with Tourette Syndrome at week 12 of treatment with Sepranolone Change Quality of Life (GTSQOL) physical/activities of daily living subscale at weeks 4, 8 and 12~To evaluate the effect on Global impression by Sepranolone at week 12 of treatment with Sepranolone Change from baseline in the Tourette Syndrome - Clinical Global Impression (TS-CGI) score at week 4, 8 and 12~Safety objectives:~to evaluate the safety and tolerability of Sepranolone in patients with Tourette Syndrome
30 subjects aged 12 to 45 years of age diagnosed with Tourette Syndrome with a YGTSS score > 20 during 30 days of baseline observation to be randomized to~continued present stable treatment (10 subjects) or~continued present stable treatment plus 10 mg of Sepranolone injected s.c. twice weekly for 12 weeks (20 patients) followed by one month of observation~Primary objective: to investigate the efficacy of Sepranolone to reduce tic severity in patients with Tourette syndrome after 12 weeks